Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Tirzepatide is a dual agonistit activates both GIP and GLP-1 receptors, while semaglutide only activates GLP-1
Post-market surveillance data suggests rates between 0.1% and 0.3% for semaglutide users, making clinical awareness and proactive screening essential before initiating treatment
In ATTAIN-2 , which specifically studied people with both obesity and type 2 diabetes (a group for whom weight loss is known to be harder), participants on the highest dose lost an average of 10.5% of body weight (about 23 lbs) over 72 weeks, while also reducing A1C by an average of 1.8%
5,10,14 Psoriasis, an autoimmune inflammatory skin condition, was shown to resolve in patients with obesity who underwent bariatric surgery, thus linking this disorder to increased adiposity
Small lifestyle changes like eating smaller meals, staying active, drinking more water and managing your gut health can help reduce symptoms
Participation in a clinical trial is the only legitimate and safe route to accessing retatrutide at this stage
